Effect of SGLT2 Inhibitors on Anemic CKD Patients

NCT07334145 · tracked via the Priya Life Science Egypt tracker

Sponsor

Sohag University

Phase

Observational

Started

2026-01-01

Last updated

2026-01-14

Condition(s) studied

Anemia in CKD Patients

Investigational drug(s) / intervention(s)

SGLT2 inhibitor

SGLT2 inhibitor: prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

Study summary

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * age more than 18 years * CKD stage 1\_4 * baseline hemoglobin 8.5 to 12.9 g/dl * stable anemia regimen for more than 8 weeks Exclusion Criteria: * dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

Primary outcome measure(s)

hemoglobin level — 12 weeks
use the hemoglobin level to assist the effect of SGLT2 inhibitors On anemia correction
change in hemoglobin level — 12 weeks
anemia correction

Trial sites (1)

Facility	City	Region	Status
Sohag University Hospital	Sohag	Sohag University

More Sohag University trials in Egypt

Peripheral Artery Disease in Regular Hemodialysis Patients Active, not recruiting

the Role of MRI in Evaluation of Low Back Pain Recruiting

Study of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults With Type 1 Diabetes Starting soon

Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety Recruiting

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07334145 on ClinicalTrials.gov ↗ ← All trials in Egypt